Compare · MMM vs NVNO
MMM vs NVNO
Side-by-side comparison of 3M Company (MMM) and enVVeno Medical Corporation (NVNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and NVNO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $92.51B, about 12327.2x NVNO ($7.5M).
- MMM has been more active in the news (5 items in the past 4 weeks vs 3 for NVNO).
- MMM has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- 3M Company
- enVVeno Medical Corporation
- Price
- -
- -
- Market cap
- $92.51B
- $7.5M
- 1M return
- +0.67%
- -
- 1Y return
- +14.53%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 0
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Latest MMM
- 3M Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 3 filed by new insider George Bobby K
- SEC Form 3 filed by new insider Cunningham Jennifer A.
- 3M Board Declares Quarterly Dividend
- Group President Chavez Rodriguez Beatriz Karina sold $663,430 worth of shares (3,635 units at $182.51), decreasing direct ownership by 21% to 14,035 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- Sr Vice President & CAO Reinseth Theresa E sold $156,544 worth of shares (924 units at $169.42), decreasing direct ownership by 26% to 2,615 units (SEC Form 4)
- Executive Vice President Banovetz John Patrick exercised 7,880 shares at a strike of $154.69 and sold $1,343,067 worth of shares (7,880 units at $170.44) (SEC Form 4)
- EVP, Chief Legal Off & Secret Rhodes Kevin H exercised 7,669 shares at a strike of $154.69 and sold $1,312,933 worth of shares (7,669 units at $171.20) (SEC Form 4)
- Group President Goralski Christian T Jr exercised 4,902 shares at a strike of $154.69 and sold $835,577 worth of shares (4,902 units at $170.46), decreasing direct ownership by 0.00% to 6,971 units (SEC Form 4)
Latest NVNO
- SEC Form S-3 filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
- SEC Form 10-Q filed by enVVeno Medical Corporation
- enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
- enVVeno Medical Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
- enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
- Director Duhay Francis sold $1,443 worth of shares (140 units at $10.30) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 2,362 units (SEC Form 4)